Procollagen II C-propeptide in joint fluid

Changes in concentration with age, time after knee injury, and osteoarthritis

L. Stefan Lohmander, Yasuo Yoshihara, Harald Roos, Tatsuo Kobayashi, Harumoto Yamada, Masayuki Shinmei

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Objective. To determine in a cross sectional study the concentrations in joint fluid of the C-propeptide of collagen II (pCol II-C) in patients with knee injury and developing osteoarthritis (OA). Methods. Synovial fluid (SF) samples were collected from knees of healthy volunteers, from patients with injury to the knee causing lesions of the anterior cruciate ligament and/or menisci, and from patients with posttraumatic or primary OA. Concentrations of pCol II-C were determined by enzyme immunoassay with a polyclonal antiserum against the bovine propeptide. Results. The median concentration of pCol II-C in joint fluid in the reference group was 1.3 ng/ml (range 0.1-5.7 ng/ml). Median concentrations of pCol II-C in joint fluid were increased 2-4-fold in all 3 study groups over that in the reference group. Very high concentrations of propeptide were noted in samples from patients younger than about 18 years. Propeptide concentrations were increased after knee injury, with a suggested peak at about 1-4 years evident for patients with cruciate ligament injury. pCol II-C levels were increased at all stages of OA development, except in the most advanced phases. Conclusion. The increased levels of pCol II-C in SF may reflect an increased rate of synthesis of collagen II in the joint cartilage of patients with knee injury and developing OA. The increase reaches a maximum well before radiographic changes indicative of OA are apparent, and occurs during a disease phase characterized by signs of increased degradation of collagen II, aggrecan, and other matrix components. Further studies of markers of matrix metabolism of cartilage, bone, and other joint tissues in human and animal models of OA may aid in the identification of process markers, individuals at risk, and new therapeutic targets.

Original languageEnglish
Pages (from-to)1765-1769
Number of pages5
JournalJournal of Rheumatology
Volume23
Issue number10
Publication statusPublished - 24-10-1996
Externally publishedYes

Fingerprint

Knee Injuries
Knee Osteoarthritis
Osteoarthritis
Joints
Synovial Fluid
Cartilage
Collagen
Aggrecans
Anterior Cruciate Ligament
Immunoenzyme Techniques
Ligaments
procollagen type II carboxy-terminal peptide
Immune Sera
Knee
Healthy Volunteers
Animal Models
Cross-Sectional Studies
Bone and Bones
Wounds and Injuries

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Cite this

Stefan Lohmander, L., Yoshihara, Y., Roos, H., Kobayashi, T., Yamada, H., & Shinmei, M. (1996). Procollagen II C-propeptide in joint fluid: Changes in concentration with age, time after knee injury, and osteoarthritis. Journal of Rheumatology, 23(10), 1765-1769.
Stefan Lohmander, L. ; Yoshihara, Yasuo ; Roos, Harald ; Kobayashi, Tatsuo ; Yamada, Harumoto ; Shinmei, Masayuki. / Procollagen II C-propeptide in joint fluid : Changes in concentration with age, time after knee injury, and osteoarthritis. In: Journal of Rheumatology. 1996 ; Vol. 23, No. 10. pp. 1765-1769.
@article{195b6896dc6c4b25b2d8c1fc4603271d,
title = "Procollagen II C-propeptide in joint fluid: Changes in concentration with age, time after knee injury, and osteoarthritis",
abstract = "Objective. To determine in a cross sectional study the concentrations in joint fluid of the C-propeptide of collagen II (pCol II-C) in patients with knee injury and developing osteoarthritis (OA). Methods. Synovial fluid (SF) samples were collected from knees of healthy volunteers, from patients with injury to the knee causing lesions of the anterior cruciate ligament and/or menisci, and from patients with posttraumatic or primary OA. Concentrations of pCol II-C were determined by enzyme immunoassay with a polyclonal antiserum against the bovine propeptide. Results. The median concentration of pCol II-C in joint fluid in the reference group was 1.3 ng/ml (range 0.1-5.7 ng/ml). Median concentrations of pCol II-C in joint fluid were increased 2-4-fold in all 3 study groups over that in the reference group. Very high concentrations of propeptide were noted in samples from patients younger than about 18 years. Propeptide concentrations were increased after knee injury, with a suggested peak at about 1-4 years evident for patients with cruciate ligament injury. pCol II-C levels were increased at all stages of OA development, except in the most advanced phases. Conclusion. The increased levels of pCol II-C in SF may reflect an increased rate of synthesis of collagen II in the joint cartilage of patients with knee injury and developing OA. The increase reaches a maximum well before radiographic changes indicative of OA are apparent, and occurs during a disease phase characterized by signs of increased degradation of collagen II, aggrecan, and other matrix components. Further studies of markers of matrix metabolism of cartilage, bone, and other joint tissues in human and animal models of OA may aid in the identification of process markers, individuals at risk, and new therapeutic targets.",
author = "{Stefan Lohmander}, L. and Yasuo Yoshihara and Harald Roos and Tatsuo Kobayashi and Harumoto Yamada and Masayuki Shinmei",
year = "1996",
month = "10",
day = "24",
language = "English",
volume = "23",
pages = "1765--1769",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "10",

}

Stefan Lohmander, L, Yoshihara, Y, Roos, H, Kobayashi, T, Yamada, H & Shinmei, M 1996, 'Procollagen II C-propeptide in joint fluid: Changes in concentration with age, time after knee injury, and osteoarthritis', Journal of Rheumatology, vol. 23, no. 10, pp. 1765-1769.

Procollagen II C-propeptide in joint fluid : Changes in concentration with age, time after knee injury, and osteoarthritis. / Stefan Lohmander, L.; Yoshihara, Yasuo; Roos, Harald; Kobayashi, Tatsuo; Yamada, Harumoto; Shinmei, Masayuki.

In: Journal of Rheumatology, Vol. 23, No. 10, 24.10.1996, p. 1765-1769.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Procollagen II C-propeptide in joint fluid

T2 - Changes in concentration with age, time after knee injury, and osteoarthritis

AU - Stefan Lohmander, L.

AU - Yoshihara, Yasuo

AU - Roos, Harald

AU - Kobayashi, Tatsuo

AU - Yamada, Harumoto

AU - Shinmei, Masayuki

PY - 1996/10/24

Y1 - 1996/10/24

N2 - Objective. To determine in a cross sectional study the concentrations in joint fluid of the C-propeptide of collagen II (pCol II-C) in patients with knee injury and developing osteoarthritis (OA). Methods. Synovial fluid (SF) samples were collected from knees of healthy volunteers, from patients with injury to the knee causing lesions of the anterior cruciate ligament and/or menisci, and from patients with posttraumatic or primary OA. Concentrations of pCol II-C were determined by enzyme immunoassay with a polyclonal antiserum against the bovine propeptide. Results. The median concentration of pCol II-C in joint fluid in the reference group was 1.3 ng/ml (range 0.1-5.7 ng/ml). Median concentrations of pCol II-C in joint fluid were increased 2-4-fold in all 3 study groups over that in the reference group. Very high concentrations of propeptide were noted in samples from patients younger than about 18 years. Propeptide concentrations were increased after knee injury, with a suggested peak at about 1-4 years evident for patients with cruciate ligament injury. pCol II-C levels were increased at all stages of OA development, except in the most advanced phases. Conclusion. The increased levels of pCol II-C in SF may reflect an increased rate of synthesis of collagen II in the joint cartilage of patients with knee injury and developing OA. The increase reaches a maximum well before radiographic changes indicative of OA are apparent, and occurs during a disease phase characterized by signs of increased degradation of collagen II, aggrecan, and other matrix components. Further studies of markers of matrix metabolism of cartilage, bone, and other joint tissues in human and animal models of OA may aid in the identification of process markers, individuals at risk, and new therapeutic targets.

AB - Objective. To determine in a cross sectional study the concentrations in joint fluid of the C-propeptide of collagen II (pCol II-C) in patients with knee injury and developing osteoarthritis (OA). Methods. Synovial fluid (SF) samples were collected from knees of healthy volunteers, from patients with injury to the knee causing lesions of the anterior cruciate ligament and/or menisci, and from patients with posttraumatic or primary OA. Concentrations of pCol II-C were determined by enzyme immunoassay with a polyclonal antiserum against the bovine propeptide. Results. The median concentration of pCol II-C in joint fluid in the reference group was 1.3 ng/ml (range 0.1-5.7 ng/ml). Median concentrations of pCol II-C in joint fluid were increased 2-4-fold in all 3 study groups over that in the reference group. Very high concentrations of propeptide were noted in samples from patients younger than about 18 years. Propeptide concentrations were increased after knee injury, with a suggested peak at about 1-4 years evident for patients with cruciate ligament injury. pCol II-C levels were increased at all stages of OA development, except in the most advanced phases. Conclusion. The increased levels of pCol II-C in SF may reflect an increased rate of synthesis of collagen II in the joint cartilage of patients with knee injury and developing OA. The increase reaches a maximum well before radiographic changes indicative of OA are apparent, and occurs during a disease phase characterized by signs of increased degradation of collagen II, aggrecan, and other matrix components. Further studies of markers of matrix metabolism of cartilage, bone, and other joint tissues in human and animal models of OA may aid in the identification of process markers, individuals at risk, and new therapeutic targets.

UR - http://www.scopus.com/inward/record.url?scp=10244234102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10244234102&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 1765

EP - 1769

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 10

ER -